[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"drug-toxicity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:drug-toxicity":22},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,67,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":23,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100593560","real-world-asparaginase-therapy-toxicity-100593560",false,"NCT07008027","Real World Asparaginase Therapy Toxicity","Inclusion Criteria:\n\n* Diagnosis of acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia\n* Enrolled on INITIALL and no more than 10 days after initiation of post-INITIALL therapy\n* Post-INITIALL therapy is:\n\n  * Standard of Care (SOC)\u002FNon Protocol Treatment Plan (NPTP) as per Total therapy or\n  * SJALL23T and not scheduled to receive venetoclax\n\nExclusion Criteria:\n\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent.","ALL",{"count":17,"type":18},200,"ESTIMATED","OBSERVATIONAL","This research study is being done to learn more about the short term and long term side effects of treatment with asparaginase drugs, which are commonly used in acute lymphoblastic leukemia (ALL) or acute lymphoblastic lymphoma (LLy) therapy.",[22],"Drug Toxicity",[24,25,26,27,28],"Asparaginase drugs","Toxicity","Acute lymphoblastic leukemia","Acute lymphoblastic lymphoma","Mixed phenotype acute leukemia","NOT_YET_RECRUITING","2026-06-29",{"date":32,"type":33},"2026-07-01","ACTUAL",{"date":35,"type":18},"2026-07",{"date":37,"type":18},"2031-07",{"name":39,"class":40},"St. Jude Children's Research Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100413113","tdm-for-optimized-outcome-in-patients-with-mrcc-100413113","NCT04659343","TDM for Optimized Outcome in Patients With mRCC.","Therapeutic Drug Monitoring for Optimized Outcome in Patients With Metastatic Renal Cell Carcinoma","Inclusion Criteria:\n\n* Patients in Denmark with medically treated metastatic renal cell carcinoma.\n\nExclusion Criteria:\n\n* No written informed consent.","18 Years",{"count":17,"type":18},"The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy and side effects. It furthermore holds microbiome characterization of CPI-treated patients.\n\nFurthermore, the investigators examines the role of anti-drug antibodies and receptor polymorphisms in CTLA-4 and PD-1 receptors in treatment failure among patients with mRCC treated with check point immunotherapy (CPI). Moreover, polymorphisms in the UGT1A1 gene will be correlated with the pazopanib treatment dose.",[53,54,22,55,56],"Kidney Cancer","Renal Cell Carcinoma Metastatic","Drug Side Effect","Drug Mechanism","RECRUITING","2026-04-28",{"date":60,"type":33},"2026-05-04",{"date":62,"type":33},"2020-11-01",{"date":64,"type":18},"2029-08-31",{"name":66,"class":40},"Niels Fristrup",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":75,"maxAge":49,"enrollmentInfo":76,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":78,"conditions":79,"keywords":87,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100478607","pharmacogenomic-association-study-in-indian-children-with-acute-lymphoblastic-leukemia-100478607","NCT05512169","Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia","Molecular and Pharmacogenetic Marker Evaluation in Relation to the Toxicity and Clinical Response of Acute Lymphoblastic Leukemia Treatment in Indian Children (MPGx-INDALL)","MPGx-INDALL","Inclusion Criteria:\n\n* Age \\> 1 year old and ≤18 years old at enrolment\n* Previously untreated\n* ALL diagnosis confirmed by morphology and flow-cytometry\n* Indian origins\n* Fulfilling IciCle treatment protocol inclusion criteria and receiving treatment as per the protocol\n* Written Informed consent to participate in the study has to be signed by the participant\u002Fparent\u002Fguardian\n\nExclusion Criteria:\n\n* Previously tretaed patients\n* Patients with Down's syndrome\n* Patients with mature B-ALL","1 Year",{"count":77,"type":18},556,"A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL). The project is an International multicenter setup. This collaborative research project between Switzerland and India includes one main center in Geneva that has conceptualized, designed, received grants for the study and two investigating centers in India (Puducherry and New-Delhi) involved in study design, patient care and recruitment for this specific study. All the participants for the study will be recruited form these two centers in India, and no patient recruitment is planned at main center i.e. Geneva.\n\nThe study will be conducted in two phases. The first aims to investigate genetic predisposition (static germline variants) to early chemotherapy treatment related toxicities (TRTs). The second aims to investigate somatic genetic markers associated with the efficacy of steroid treatment among patients undergoing the standardized IciCLe-ALL-14 treatment protocol. A total of 500 children with ALL will be recruited to investigate primary objective of the study i.e. TRT, and a subset of 250 patients will be included to investigate another research question i.e. response to steroid therapy.",[80,81,82,83,84,22,85,86],"ALL, Childhood","Pediatric Cancer","Toxicity, Drug","Adverse Drug Event","Relapse Leukemia","Drug Effect","Drug Interaction",[88,89,90,91,92,93,94,95,96,97,98,99,100,101],"Pharmacogenetics","Pharmacogenomics","Genetic polymorphism","Sequencing","Genotyping","Indian","Pediatrics","SNP","gene variant","germline genetic variant","somatic variant","biomarker","steroid response","genetic predisposition","2026-01-13",{"date":104,"type":33},"2026-01-15",{"date":106,"type":33},"2022-12-01",{"date":108,"type":18},"2027-03-30",{"name":110,"class":40},"University of Geneva, Switzerland",2,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":120,"targetDuration":122,"studyType":19,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":41},"100415933","atrial-fibrillation-in-active-cancer-patients-100415933","NCT04696081","Atrial Fibrillation in Active Cancer Patients","Multicenter International Prospective Registry to Identify Major Cardiovascular Events Associated With the Occurrence of Atrial Fibrillation in Active Cancer Patients","AFIB-CANCER","Inclusion Criteria:\n\n* adult patients\n* outpatients or hospitalized patients\n* with a confirmed cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor, known intracerebral metastases, or acute leukemia) and an active cancer (defined as cancer that had been diagnosed within the past 6 months or recurrent locally advanced or metastatic cancer, for which anticancer treatment was being given at the time of enrollment or during 6 months before enrollment)\n* at least 1 episode of atrial fibrillation (new onset AF occuring after cancer diagnosis or history of paroxysmal of persistant AF prior to cancer diagnosis and an AF recurrence after cancer diagnosis)\n* in sinus rhythm at the time of cancer diagnosis\n\nExclusion Criteria:\n\n* patient with palliative cares or other conditions resulting in short term death (death expected in the month following atrial fibrillation occurrence)\n* history of long-standing persistant or permanent AF prior to cancer diagnosis",{"count":121,"type":18},1000,"2 Years","Atrial fibrillation is a common complication of both cancer and anticancer drugs but the consequences of such events remain poorly known and are not adressed in both phase III oncological trials and cardiological guidelines. The objective of this study is to create a prospective multicenter international registry of adult patients with an active cancer and experiencing atrial fibrillation to study major cardiovascular events occurrence during a 1 year follow-up.",[125,22,126,127],"Cancer","Atrial Fibrillation","Cardiovascular Complication","2024-08-08",{"date":130,"type":33},"2024-08-09",{"date":132,"type":33},"2021-09-01",{"date":134,"type":18},"2026-01-01",{"name":136,"class":40},"University Hospital, Caen"]